Summit Therapeutics appoints Dr. Robert Booth to Board of Directors; Dr. Urte Gayko resigns from Board

Summit Therapeutics Inc.

Dr. Robert Booth appointed to Board effective September 28, 2022; will join Nominating and Corporate Governance Committee.
Dr. Booth initiated the BTK inhibitor program at Celera Genomics that led to Pharmacyclics' blockbuster drug Imbruvica (ibrutinib).
Dr. Booth received stock option grant per non-employee director compensation policy and standard indemnification agreement.
Dr. Urte Gayko resigned from Board to focus on her full-time role as Head of Regulatory, Safety, and Quality; resignation not due to any disagreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Urte Gayko

Director

SMMT · Summit Therapeutics Inc.

Effective: 2022-09-28
Successor: Robert Booth
Filed: October 3, 2022, 7:59 PM ET

effective September 28, 2022, Urte Gayko resigned from the Board of the Company in order to create a vacancy for Dr. Robert Booth, PhD

Appointed

Robert Booth

Director

SMMT · Summit Therapeutics Inc.

Effective: 2022-09-28
Successor: Urte Gayko
Filed: October 3, 2022, 7:59 PM ET

On September 28, 2022, the Board unanimously approved (i) the election of Dr. Robert Booth, PhD as a director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Urte Gayko resigned as Director at Summit Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

effective September 28, 2022, Urte Gayko resigned from the Board of the Company in order to create a vacancy for Dr. Robert Booth, PhD

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Booth was appointed as Director at Summit Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 28, 2022, the Board unanimously approved (i) the election of Dr. Robert Booth, PhD as a director

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-22-000109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.